Hyloris Pharmaceuticals (HYL) investor relations material

Executive summary

• Revenue increased by 56% year-over-year to €4.7 million, with net loss reduced to €1.9 million, the lowest since IPO.

• Strategic execution advanced across Mavericks, Core Drivers, and Promising Seeds, including new and expanded licensing agreements and program progress.

• Portfolio review led to discontinuation of select programs, sharpening focus on high-potential assets.

• Focused on advancing regulatory submissions, approvals, launches, and licensing agreements to drive recurring commercial income.

Financial highlights

• Total revenue rose 56% year-over-year to €4.7 million, mainly from higher milestone income and new licensing deals.

• Operating income increased 47% to €5.6 million; operating expenses stable at €7.6 million.

• Net loss narrowed to €1.9 million from €3.6 million in H1 2025.

• Equity at €24.9 million and cash/cash equivalents at €8.7 million as of June 30, 2026.

• R&D expenses decreased by 16% to €4.2 million; G&A expenses increased by 15%.

Outlook and guidance

• Preparing regulatory submissions for Aspirin IV and Dofetilide IV in H2 2026.

• Advancing Alenura™, HY-094 (IV Iron), Metolazone IV, and Milrinone ER toward key clinical and regulatory milestones.

• Evaluating selective new opportunities, including a potential addition targeting a prevalent orphan disease.

• Expecting upfront payments from ongoing licensing discussions and additional financial flexibility from €6 million in new funding.

• Strategic focus on U.S. cardiovascular portfolio commercialization, including potential partnerships.